Taro Announces T2007 Clinical Trials (OTC:TAROF)
Taro Pharmaceutical Industries Ltd (OTC:TAROF) has announced that they have begun the Phase 1 of clinical trials in Canada with T2007 which is second in the Company’s class of proprietary non-sedating barbiturate compounds to be approved for studies in humans. Taro Pharmaceutical Industries is a multinational science based pharmaceutical company which is dedicated to meet the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. The Company mainly manufactures over the counter pharmaceutical products primarily in the United States, Canada and Israel. The Company also develops active pharmaceutical ingredients for use in its finished dosage form products.
T2007 is the sodium salt of diphenylbarbituric acid (DPB). Plans for T2007 are currently directed at its use as an antiepileptic agent. In previous Phase II studies conducted in Canada, T2000, a prodrug (precursor) of DPB, produced functional improvement in patients with essential tremor. The Company announced last week that the United States Food and Drug Administration have granted an Investigational New Drug (IND) exemption to permit clinical studies on T2000 in the U.S. The Company expects that its experience with T2000 will facilitate its development of T2007.
In animal models, DPB has efficacy comparable to phenobarbital, a long-established clinical treatment for epilepsy. Phenobarbital remains the most commonly prescribed antiepileptic drug throughout the world, although its use has always been limited by its sedating side effects and it has been largely replaced by newer agents in Europe and North America.
Related Articles:
